<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192348</url>
  </required_header>
  <id_info>
    <org_study_id>D153-P518</org_study_id>
    <nct_id>NCT00192348</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, Trivalent, Types A &amp; B, Live Cold Adapted (CAIV-T) in Healthy Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      Trial to compare the safety and tolerability of one and two doses of influenza virus vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study was to compare the safety and tolerability of one and two doses&#xD;
      of influenza virus vaccine, trivalent, types A and B, live cold-adapted liquid (CAIV-T) with&#xD;
      placebo when administered intranasally to healthy infants aged 6 &lt; 24 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date>December 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>- To compare the safety and tolerability of one and two doses of influenza virus vaccine, trivalent,(CAIV-T) with placebo when administered intranasally</measure>
  </primary_outcome>
  <enrollment>120</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children at least 6 weeks of age and less than 24 weeks of age at the time of&#xD;
             enrollment, of &gt;37 weeks gestational age and with a birth weight of &gt;2500 g, and in&#xD;
             good health as determined by medical history, physical examination and clinical&#xD;
             judgment;&#xD;
&#xD;
          -  whose parent/legal guardian provided written informed consent after the nature of the&#xD;
             study was explained;&#xD;
&#xD;
          -  who, along with their parent or legal guardian, were available for the three month&#xD;
             duration of the trial (from enrollment to study completion);&#xD;
&#xD;
          -  whose parent(s)/legal guardian(s), could be reached by study staff for the&#xD;
             post-vaccination contacts [telephone, clinic or home visit].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  whose parents or legal guardians were perceived to be unavailable or difficult to&#xD;
             contact for evaluation or study visits during the study period;&#xD;
&#xD;
          -  with any serious chronic disease (e.g., with signs of cardiac or renal failure or&#xD;
             severe malnutrition), including progressive neurological disease;&#xD;
&#xD;
          -  with Down's syndrome or other known cytogenetic disorders;&#xD;
&#xD;
          -  with a known or suspected disease of the immune system or those receiving&#xD;
             immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents;&#xD;
&#xD;
          -  who received any blood products, including immunoglobulin, in the period from birth&#xD;
             through to the conclusion of the study;&#xD;
&#xD;
          -  had an immunosuppressed or an immunocompromised individual living in the same&#xD;
             household;&#xD;
&#xD;
          -  with a documented history of hypersensitivity to egg or egg protein or any other&#xD;
             component of the study vaccines or placebo;&#xD;
&#xD;
          -  who were administered any live virus vaccine within one month prior to enrollment; or&#xD;
             expected to receive another live vaccine within 1 month of vaccination in the study.&#xD;
&#xD;
          -  for whom there was intent to administer any other investigational vaccine or agent&#xD;
             from one month prior to enrollment through to the conclusion of the study;&#xD;
&#xD;
          -  who received a dose of influenza treatment (commercial or investigational) two weeks&#xD;
             prior to enrollment. The prophylactic use of influenza antivirals was not permitted;&#xD;
&#xD;
          -  who, at anytime prior to study enrollment, received any influenza vaccine (commercial&#xD;
             or investigational);&#xD;
&#xD;
          -  with a respiratory illness with wheezing within two weeks prior to each dose of study&#xD;
             vaccine;&#xD;
&#xD;
          -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two&#xD;
             weeks prior to enrollment or for which use was anticipated during the study;&#xD;
&#xD;
          -  with any medical conditions that in the opinion of the investigator might have&#xD;
             interfered with interpretation of the study results.&#xD;
&#xD;
        Note: Pregnancy in any person who had regular contact with the subjects was not considered&#xD;
        a contraindication to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>24 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Tampere</name>
      <address>
        <city>Tampere</city>
        <zip>33014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

